200 related articles for article (PubMed ID: 30832603)
1. Modeling to capture bystander-killing effect by released payload in target positive tumor cells.
Byun JH; Jung IH
BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
3. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
4. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
Burton JK; Bottino D; Secomb TW
AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
[TBL] [Abstract][Full Text] [Related]
5. Bystander effect of antibody-drug conjugates: fact or fiction?
Giugliano F; Corti C; Tarantino P; Michelini F; Curigliano G
Curr Oncol Rep; 2022 Jul; 24(7):809-817. PubMed ID: 35305211
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class.
Calopiz MC; Linderman JJ; Thurber GM
Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
9. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
10. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
[TBL] [Abstract][Full Text] [Related]
11. Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors.
Guo Y; Shen Z; Zhao W; Lu J; Song Y; Shen L; Lu Y; Wu M; Shi Q; Zhuang W; Qiu Y; Sheng J; Zhou Z; Fang L; Che J; Dong X
Adv Sci (Weinh); 2024 Apr; 11(13):e2306309. PubMed ID: 38269648
[TBL] [Abstract][Full Text] [Related]
12. Cell killing by antibody-drug conjugates.
Kovtun YV; Goldmacher VS
Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
14. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
Singh AP; Shah DK
J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
[TBL] [Abstract][Full Text] [Related]
15. A mechanistic tumor penetration model to guide antibody drug conjugate design.
Vasalou C; Helmlinger G; Gomes B
PLoS One; 2015; 10(3):e0118977. PubMed ID: 25786126
[TBL] [Abstract][Full Text] [Related]
16. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
[TBL] [Abstract][Full Text] [Related]
17. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher AH; Brown MP
Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody.
Menezes B; Khera E; Calopiz M; Smith MD; Ganno ML; Cilliers C; Abu-Yousif AO; Linderman JJ; Thurber GM
AAPS J; 2022 Oct; 24(6):107. PubMed ID: 36207468
[TBL] [Abstract][Full Text] [Related]
19. The Analysis of Key Factors Related to ADCs Structural Design.
Tang H; Liu Y; Yu Z; Sun M; Lin L; Liu W; Han Q; Wei M; Jin Y
Front Pharmacol; 2019; 10():373. PubMed ID: 31068807
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modeling of antibody drug conjugates with the target and tubulin dynamics to predict AUC.
Byun JH; Jung IH
J Theor Biol; 2018 Apr; 443():113-124. PubMed ID: 29409861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]